GEMCITABINE- gemcitabine hydrochloride injection, powder, lyophilized, for solution 
Hospira, Inc.

----------

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use GEMCITABINE FOR INJECTION safely and effectively. See full prescribing information for GEMCITABINE FOR INJECTION.

GEMCITABINE for injection, powder, lyophilized, for solution for intravenous use

Initial U.S. Approval: 1996

RECENT MAJOR CHANGES

Dosage and Administration, Dose Modifications for
Non-Hematologic Adverse Reactions (2.5)                         4/2016

Warnings and Precautions, Posterior Reversible Encephalopathy
Syndrome (5.9)                                                                     4/2016

INDICATIONS AND USAGE

Gemcitabine is a nucleoside metabolic inhibitor indicated:

In combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. (1.1)
In combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. (1.2)
In combination with cisplatin for the treatment of non-small cell lung cancer. (1.3)
As a single agent for the treatment of pancreatic cancer. (1.4)

DOSAGE AND ADMINISTRATION

Gemcitabine for injection, USP is for intravenous use only.

Ovarian Cancer: 1,000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle. (2.1)
Breast Cancer: 1,250 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle. (2.2)
Non-Small Cell Lung Cancer: 1,000 mg/m2 over 30 minutes on Days 1, 8, and 15 of each 28-day cycle or 1,250 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle. (2.3)
Pancreatic Cancer: 1,000 mg/m2 over 30 minutes once weekly for the first 7 weeks, then one week rest, then once weekly for 3 weeks of each 28-day cycle. (2.4)

DOSAGE FORMS AND STRENGTHS

2 g single-dose vial for injection. (3)

CONTRAINDICATIONS

Patients with a known hypersensitivity to gemcitabine. (4)

WARNINGS AND PRECAUTIONS

Schedule-dependent toxicity: Increased toxicity with infusion time greater than 60 minutes or dosing more frequently than once weekly. (5.1)
Myelosuppression: Monitor for myelosuppression prior to each cycle and reduce or withhold dose for severe myelosuppression. (5.2, 5.7)
Pulmonary Toxicity and Respiratory Failure: Discontinue gemcitabine for injection immediately for unexplained new or worsening dyspnea or evidence of severe pulmonary toxicity. (5.3)
Hemolytic-Uremic Syndrome (HUS): Monitor renal function prior to initiation and during therapy. Discontinue gemcitabine for injection for HUS or severe renal impairment. (5.4)
Hepatic Toxicity: Monitor hepatic function prior to initiation and during therapy. Discontinue gemcitabine for injection for severe hepatic toxicity. (5.5)
Embryofetal Toxicity: Can cause fetal harm. Advise women of potential risk to the fetus. (5.6, 8.1)
Exacerbation of Radiation Therapy Toxicity: May cause severe and life-threatening toxicity when administered during or within 7 days of radiation therapy. (5.7)
Capillary Leak Syndrome: Discontinue gemcitabine for injection. (5.8)
Posterior reversible encephalopathy syndrome (PRES): Discontinue gemcitabine for injection. (5.9)

ADVERSE REACTIONS

The most common adverse reactions for the single agent (≥ 20%) are nausea/vomiting, anemia, hepatic transaminitis, neutropenia, increased alkaline phosphatase, proteinuria, fever, hematuria, rash, thrombocytopenia, dyspnea, and peripheral edema. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 2/2017

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

1.1 Ovarian Cancer

1.2 Breast Cancer

1.3 Non-Small Cell Lung Cancer

1.4 Pancreatic Cancer

2 DOSAGE AND ADMINISTRATION

2.1 Ovarian Cancer

2.2 Breast Cancer

2.3 Non-Small Cell Lung Cancer

2.4 Pancreatic Cancer

2.5 Dose Modifications for Non-Hematologic Adverse Reactions

2.6 Preparation and Administration Precautions

2.7 Preparation for Intravenous Infusion Administration

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Schedule-dependent Toxicity

5.2 Myelosuppression

5.3 Pulmonary Toxicity and Respiratory Failure

5.4 Hemolytic Uremic Syndrome

5.5 Hepatic Toxicity

5.6 Embryofetal Toxicity

5.7 Exacerbation of Radiation Therapy Toxicity

5.8 Capillary Leak Syndrome

5.9 Posterior Reversible Encephalopathy Syndrome

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

6.2 Post-Marketing Experience

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.3 Nursing Mothers

8.4 Pediatric Use

8.5 Geriatric Use

8.6 Renal Impairment

8.7 Hepatic Impairment

8.8 Gender

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

14.1 Ovarian Cancer

14.2 Breast Cancer

14.3 Non-Small Cell Lung Cancer (NSCLC)

14.4 Pancreatic Cancer

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

16.2 Storage and Handling

17 PATIENT COUNSELING INFORMATION

*
Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Ovarian Cancer

Gemcitabine in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.

1.2 Breast Cancer

Gemcitabine in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.

1.3 Non-Small Cell Lung Cancer

Gemcitabine is indicated in combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer.

1.4 Pancreatic Cancer

Gemcitabine is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine is indicated for patients previously treated with 5-FU.

2 DOSAGE AND ADMINISTRATION

2.1 Ovarian Cancer

Recommended Dose and Schedule

The recommended dose of gemcitabine is 1,000 mg/m2 as an intravenous infusion over 30 minutes on Days 1 and 8 of each 21-day cycle, in combination with carboplatin AUC 4 intravenously after gemcitabine administration on Day 1 of each 21-day cycle. Refer to carboplatin prescribing information for additional information.

Dose Modifications

Recommended gemcitabine dose modifications for myelosuppression are described in Table 1 and Table 2 [see Warnings and Precautions (5.2)]. Refer to Dosage and Administration (2.5) for recommendations for non-hematologic adverse reactions.

Table 1: Dosage Reduction Guidelines for Gemcitabine for Myelosuppression on Day of Treatment in Ovarian Cancer

Treatment Day

Absolute granulocyte count

(x 106/L)

Platelet count

(x 106/L)

% of full dose

Day 1

≥1,500

and

≥100,000

100%

<1,500

or

<100,000

Delay Treatment Cycle

Day 8

≥1,500

and

≥100,000

100%

1,000-1,499

or

75,000-99,999

50%

<1,000

or

<75,000

Hold

Table 2: Gemcitabine Dose Modification for Myelosuppression in Previous Cycle In Ovarian Cancer

Occurrence

Myelosuppression During Treatment Cycle

Dose Modification

Initial Occurrence

Absolute granulocyte count less than 500 x 106/L for more than 5 days Absolute granulocyte count less than 100 x 106/L for more than 3 days

Febrile neutropenia

Platelets less than 25,000x106/L

Cycle delay of more than one week due to toxicity

Permanently reduce gemcitabine to 800 mg/m2 on Days 1 and 8

Subsequent Occurrence

If any of the above toxicities occur after the initial dose reduction

Permanently reduce gemcitabine dose to 800 mg/m2 on Day 1 only

2.2 Breast Cancer

Recommended Dose and Schedule

The recommended dose of gemcitabine is 1,250 mg/m2 intravenously over 30 minutes on Days 1 and 8 of each 21-day cycle that includes paclitaxel. Paclitaxel should be administered at 175 mg/m2 on Day 1 as a 3 hour intravenous infusion before gemcitabine administration.

Dose Modifications

Recommended dose modifications for gemcitabine for myelosuppression are described in Table 3 [see Warnings and Precautions (5.2)]. Refer to Dosage and Administration (2.5) for recommendations for non-hematologic adverse reactions.

Table 3: Recommended Dose Reductions for Gemcitabine for Myelosuppression on Day of Treatment in Breast Cancer

Treatment Day

Absolute granulocyte count

(x 106/L)

Platelet count

(x 106/L)

% of full dose

Day 1

≥1,500

and

≥100,000

100%

less than 1,500

or

less than 100,000

Hold

Day 8

≥1,200

and

>75,000

100%

1,000-1,199

or

50,000-75,000

75%

700-999

and

≥50,000

50%

<700

or

<50,000

Hold

2.3 Non-Small Cell Lung Cancer

Recommended Dose and Schedule

Every 4-week schedule

The recommended dose of gemcitabine is 1,000 mg/m2 intravenously over 30 minutes on Days 1, 8, and 15 in combination with cisplatin therapy. Administer cisplatin intravenously at 100 mg/m2 on Day 1 after the infusion of gemcitabine.

Every 3-week schedule

The recommended dose of gemcitabine is 1,250 mg/m2 intravenously over 30 minutes on Days 1 and 8 in combination with cisplatin therapy. Administer cisplatin intravenously at 100 mg/m2 on Day 1 after the infusion of gemcitabine.

Dose Modifications

Recommended dose modifications for gemcitabine myelosuppression are described in Table 4 [see Warnings and Precautions (5.2)]. Refer to Dosage and Administration (2.5) for gemcitabine recommendations for non-hematologic adverse reactions.

2.4 Pancreatic Cancer

Recommended Dose and Schedule

The recommended dose of gemcitabine is 1,000 mg/m2 over 30 minutes intravenously. The recommended treatment schedule is as follows:

Weeks 1-8: weekly dosing for the first 7 weeks followed by one week rest.
After week 8: weekly dosing on Days 1, 8, and 15 of 28-day cycles.

Dose Modifications

Recommended dose modifications for gemcitabine for myelosuppression are described in Table 4 [see Warnings and Precautions (5.2)]. Refer to Dosage and Administration (2.5) for recommendations for non-hematologic adverse reactions.

Patients receiving gemcitabine should be monitored prior to each dose with a complete blood count (CBC), including differential and platelet count. If marrow suppression is detected, therapy should be modified or suspended according to the guidelines in Table 4.

Table 4: Recommended Dose Reductions for Gemcitabine for Myelosuppression in Pancreatic Cancer and Non-Small Cell Lung Cancer

Absolute granulocyte count

(x 106/L)

Platelet count

(x 106/L)

% of full dose

≥1,000

and

≥100,000

100%

500-999

or

50,000-99,999

75%

<500

or

<50,000

Hold

2.5 Dose Modifications for Non-Hematologic Adverse Reactions

Permanently discontinue gemcitabine for any of the following:

Unexplained dyspnea or other evidence of severe pulmonary toxicity
Severe hepatic toxicity
Hemolytic-uremic syndrome
Capillary leak syndrome
Posterior reversible encephalopathy syndrome

Withhold gemcitabine or reduce dose by 50% for other severe (Grade 3 or 4) non-hematological toxicity until resolved. No dose modifications are recommended for alopecia, nausea, or vomiting.

2.6 Preparation and Administration Precautions

Exercise caution and wear gloves when preparing gemcitabine solutions. Immediately wash the skin thoroughly or rinse the mucosa with copious amounts of water if gemcitabine contacts the skin or mucus membranes. Death has occurred in animal studies due to dermal absorption. For further guidance on handling gemcitabine go to "OSHA Hazardous Drugs" (refer to antineoplastic weblinks including OSHA Technical Manual) at OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html

2.7 Preparation for Intravenous Infusion Administration

The recommended diluent for reconstitution of gemcitabine for injection is 0.9% Sodium Chloride Injection without preservatives. Due to solubility considerations, the maximum concentration for gemcitabine upon reconstitution is 40 mg/mL. Reconstitution at concentrations greater than 40 mg/mL may result in incomplete dissolution, and should be avoided.

To reconstitute, add 50 mL of 0.9% Sodium Chloride Injection to the 2 g vial. Shake to dissolve. This dilution yields a gemcitabine concentration of 38 mg/mL which includes accounting for the displacement volume of the lyophilized powder (2.6 mL for the 2 g vial). The total volume upon reconstitution will be 52.6 mL. Complete withdrawal of the vial contents will provide 2 g of gemcitabine, respectively. The appropriate amount of drug may be administered as prepared or further diluted with 0.9% Sodium Chloride Injection to concentrations as low as 0.1 mg/mL.

Reconstituted gemcitabine for injection is a clear and colorless to light straw-colored solution. After reconstitution with 0.9% Sodium Chloride Injection, the pH of the resulting solution lies in the range of 2.7 to 3.3. The solution should be inspected visually for particulate matter and discoloration, prior to administration, whenever solution or container permit. If particulate matter or discoloration is found, do not administer.

When prepared as directed, gemcitabine solutions are stable for 24 hours at controlled room temperature 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Discard unused portion. Solutions of reconstituted gemcitabine should not be refrigerated, as crystallization may occur.

The compatibility of gemcitabine with other drugs has not been studied. No incompatibilities have been observed with infusion bottles or polyvinyl chloride bags and administration sets.

3 DOSAGE FORMS AND STRENGTHS

Gemcitabine for injection, USP is a white to off-white lyophilized powder available in sterile single-dose vials containing 2 g gemcitabine.

4 CONTRAINDICATIONS

Gemcitabine is contraindicated in patients with a known hypersensitivity to gemcitabine.

5 WARNINGS AND PRECAUTIONS

5.1 Schedule-dependent Toxicity

In clinical trials evaluating the maximum tolerated dose of gemcitabine, prolongation of the infusion time beyond 60 minutes or more frequent than weekly dosing resulted in an increased incidence of clinically significant hypotension, severe flu-like symptoms, myelosuppression, and asthenia. The half-life of gemcitabine for injection is influenced by the length of the infusion [see Clinical Pharmacology (12.3)].

5.2 Myelosuppression

Myelosuppression manifested by neutropenia, thrombocytopenia, and anemia occurs with gemcitabine as a single agent and the risks are increased when gemcitabine is combined with other cytotoxic drugs. In clinical trials, Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred in 25%, 8%, and 5%, respectively of patients receiving single-agent gemcitabine. The frequencies of Grade 3-4 neutropenia, anemia, and thrombocytopenia varied from 48% to 71%, 8 to 28%, and 5 to 55%, respectively, in patients receiving gemcitabine in combination with another drug.

5.3 Pulmonary Toxicity and Respiratory Failure

Pulmonary toxicity, including interstitial pneumonitis, pulmonary fibrosis, pulmonary edema, and adult respiratory distress syndrome (ARDS), has been reported. In some cases, these pulmonary events can lead to fatal respiratory failure despite discontinuation of therapy. The onset of pulmonary symptoms may occur up to 2 weeks after the last dose of gemcitabine. Discontinue gemcitabine in patients who develop unexplained dyspnea, with or without bronchospasm, or have any evidence of pulmonary toxicity [see Adverse Reactions (6.1 and 6.2)].

5.4 Hemolytic Uremic Syndrome

Hemolytic uremic syndrome, including fatalities from renal failure or the requirement for dialysis, can occur in patients treated with gemcitabine. In clinical trials, HUS was reported in 6 of 2,429 patients (0.25%). Most fatal cases of renal failure were due to HUS [see Adverse Reactions (6.1 and 6.2)]. Assess renal function prior to initiation of gemcitabine and periodically during treatment. Consider the diagnosis of HUS in patients who develops anemia with evidence of microangiopathic hemolysis, elevation of bilirubin or LDH, or reticulocytosis; severe thrombocytopenia; or evidence of renal failure (elevation of serum creatinine or BUN) [see Dosage and Administration (2.5) and Use in Specific Populations (8.6)]. Permanently discontinue gemcitabine in patients with HUS or severe renal impairment. Renal failure may not be reversible even with discontinuation of therapy.

5.5 Hepatic Toxicity

Drug-induced liver injury, including liver failure and death, has been reported in patients receiving gemcitabine alone or in combination with other potentially hepatotoxic drugs [see Adverse Reactions (6.1 and 6.2)]. Administration of gemcitabine in patients with concurrent liver metastases or a pre-existing medical history of hepatitis, alcoholism, or liver cirrhosis can lead to exacerbation of the underlying hepatic insufficiency [see Use in Specific Populations (8.7)]. Assess hepatic function prior to initiation of gemcitabine and periodically during treatment. Discontinue gemcitabine in patients that develop severe liver injury.

5.6 Embryofetal Toxicity

Gemcitabine can cause fetal harm when administered to a pregnant woman, based on its mechanism of action. Gemcitabine was teratogenic, embryotoxic, and fetotoxic in mice and rabbits. If this drug is used during pregnancy, or if a woman becomes pregnant while taking gemcitabine, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations (8.1)].

5.7 Exacerbation of Radiation Therapy Toxicity

Gemcitabine is not indicated for use in combination with radiation therapy.

Concurrent (given together or ≤7 days apart) - Life-threatening mucositis, especially esophagitis and pneumonitis occurred in a trial in which gemcitabine was administered at a dose of 1,000 mg/m2 to patients with non-small cell lung cancer for up to 6 consecutive weeks concurrently with thoracic radiation.

Non-concurrent (given >7 days apart) - Excessive toxicity has not been observed when gemcitabine is administered more than 7 days before or after radiation. Radiation recall has been reported in patients who receive gemcitabine after prior radiation.

5.8 Capillary Leak Syndrome

Capillary leak syndrome (CLS) with severe consequences has been reported in patients receiving gemcitabine as a single agent or in combination with other chemotherapeutic agents. Discontinue gemcitabine if CLS develops during therapy.

5.9 Posterior Reversible Encephalopathy Syndrome

Posterior reversible encephalopathy syndrome (PRES) has been reported in patients receiving gemcitabine as a single agent or in combination with other chemotherapeutic agents. PRES can present with headache, seizure, lethargy, hypertension, confusion, blindness, and other visual and neurologic disturbances. Confirm the diagnosis of PRES with magnetic resonance imaging (MRI) and discontinue gemcitabine if PRES develops during therapy.

6 ADVERSE REACTIONS

The following serious adverse reactions are discussed in greater detail in another section of the label

Schedule-dependent Toxicity [see Warnings and Precautions (5.1)]
Myelosuppression [see Warnings and Precautions (5.2)]
Pulmonary Toxicity and Respiratory Failure [see Warnings and Precautions (5.3)]
Hemolytic Uremic Syndrome [see Warnings and Precautions (5.4)]
Hepatic Toxicity [see Warnings and Precautions (5.5)]
Embryofetal Toxicity [see Warnings and Precautions (5.6), Use in Specific Populations (8.1), and Nonclinical Toxicology (13.1)]
Exacerbation of Radiation Toxicity [see Warnings and Precautions (5.7)]
Capillary Leak Syndrome [see Warnings and Precautions (5.8)]
Posterior Reversible Encephalopathy Syndrome [see Warnings and Precautions (5.9)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Single-Agent Use:

The data described below reflect exposure to gemcitabine as a single-agent administered at doses between 800 mg/m2 to 1,250 mg/m2 over 30 minutes intravenously, once weekly, in 979 patients with a variety of malignancies. The most common (≥20%) adverse reactions of single-agent gemcitabine are nausea/vomiting, anemia, increased ALT, increased AST, neutropenia, increased alkaline phosphatase, proteinuria, fever, hematuria, rash, thrombocytopenia, dyspnea, and edema. The most common (≥5%) Grade 3 or 4 adverse reactions were neutropenia, nausea/vomiting; increased ALT, increase alkaline phosphatase, anemia, increased AST, and thrombocytopenia. Approximately 10% of the 979 patients discontinued gemcitabine due to adverse reactions. Adverse reactions resulting in discontinuation of gemcitabine in 2% of 979 patients were cardiovascular adverse events (myocardial infarction, cerebrovascular accident, arrhythmia, and hypertension) and adverse reactions resulting in discontinuation of gemcitabine in less than 1% of the 979 patients were anemia, thrombocytopenia, hepatic dysfunction, renal dysfunction, nausea/vomiting, fever, rash, dyspnea, hemorrhage, infection, stomatitis, somnolence, flu-like syndrome, and edema.

Table 5 presents the incidence of adverse reactions reported in 979 patients with various malignancies receiving single-agent gemcitabine across 5 clinical trials. Table 5 includes all clinical adverse reactions, reported in at least 10% of patients. A listing of clinically significant adverse reactions is provided following the table.

Table 5: Selected Per-Patient Incidence of Adverse Events in Patients Receiving Single-Agent Gemcitabinea
a       Grade based on criteria from the World Health Organization (WHO).
b       N=699-974; all patients with laboratory or non-laboratory data.
c       Regardless of causality.
d       For approximately 60% of patients, non-laboratory adverse events were graded only if assessed to be possibly drug-related.

All Patientsb

All Grades

Grade 3

Grade 4

Laboratoryc

Hematologic

   Anemia

   Neutropenia

   Thrombocytopenia

68

63

24

7

19

4

1

6

1

Hepatic

   Increased ALT

   Increased AST

   Increased Alkaline

   Phosphatase

   Hyperbilirubinemia

68

67

55

 

13

8

6

7

 

2

2

2

2

 

<1

Renal

   Proteinuria

   Hematuria

   Increased BUN

   Increased Creatinine

45

35

16

8

<1

<1

0

<1

0

0

0

0

Non-laboratoryd

   Nausea and Vomiting

   Fever

   Rash

   Dyspnea

   Diarrhea

   Hemorrhage

   Infection

   Alopecia

   Stomatitis

   Somnolence

   Paresthesias

69

41

30

23

19

17

16

15

11

11

10

13

2

<1

3

1

<1

1

<1

<1

<1

<1

1

0

0

<1

0

<1

<1

0

0

<1

0

Transfusion requirements - Red blood cell transfusions (19%); platelet transfusions (<1%)
Fever - Fever occurred in the absence of clinical infection and frequently in combination with other flu-like symptoms.
Pulmonary - Dyspnea unrelated to underlying disease and sometimes accompanied by bronchospasm.
Edema - Edema (13%), peripheral edema (20%), and generalized edema (<1%); <1% of patients discontinued gemcitabine due to edema.
Flu-like Symptoms - Characterized by fever, asthenia, anorexia, headache, cough, chills, myalgia, asthenia, insomnia, rhinitis, sweating, and/or malaise (19%); <1% of patients discontinued gemcitabine due to flu-like symptoms.
Infection - Sepsis (<1%).
Extravasation - Injection-site reactions (4%).
Allergic - Bronchospasm (<2%); anaphylactoid reactions [see Contraindications (4)].

Non-Small Cell Lung Cancer:

Table 6 presents the incidence of selected adverse reactions, occurring in >10% of gemcitabine-treated patients and at a higher incidence in the gemcitabine plus cisplatin arm, reported in a randomized trial of gemcitabine plus cisplatin (n=262) administered in 28-day cycles as compared to cisplatin alone (n=260) in patients receiving first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) [see Clinical Studies (14.3)].

Patients randomized to gemcitabine plus cisplatin received a median of 4 cycles of treatment and those randomized to cisplatin received a median of 2 cycles of treatment. In this trial, the requirement for dose adjustments (>90% versus 16%), discontinuation of treatment for adverse reactions (15% versus 8%), and the proportion of patients hospitalized (36% versus 23%) were all higher for patients receiving gemcitabine plus cisplatin arm compared to those receiving cisplatin alone. The incidence of febrile neutropenia (9/262 versus 2/260), sepsis (4% versus 1%), Grade 3 cardiac dysrhythmias (3% versus <1%) were all higher in the gemcitabine plus cisplatin arm compared to the cisplatin alone arm.

The two-drug combination was more myelosuppressive with 4 (1.5%) possibly treatment-related deaths, including 3 resulting from myelosuppression with infection and one case of renal failure associated with pancytopenia and infection. No deaths due to treatment were reported on the cisplatin arm.

Table 6: Per-Patient Incidence of Selected Adverse Reactions from Randomized Trial of Gemcitabine Plus Cisplatin versus Single-Agent Cisplatin in Patients with NSCLC Occurring at Higher Incidence in Gemcitabine-Treated Patients [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)]a
a      National Cancer Institute Common Toxicity Criteria (CTC) for severity grading.
b      N=217-253; all gemcitabine plus cisplatin patients with laboratory or non-laboratory data. Gemcitabine at 1,000 mg/m2 on Days 1, 8, and 15 and cisplatin at 100 mg/m2 on Day 1 every 28 days.
c      N=213-248; all cisplatin patients with laboratory or non-laboratory data. Cisplatin at 100 mg/m2 on Day 1 every 28 days.
d      Regardless of causality.
e      Percent of patients receiving transfusions. Percent transfusions are not CTC-graded events.
f      Non-laboratory events were graded only if assessed to be possibly drug-related.

Gemcitabine plus Cisplatinb

Cisplatinc

All Grades

Grade 3

Grade 4

All Grades

Grade 3

Grade 4

Laboratoryd

Hematologic

   Anemia

   RBC Transfusione

   Neutropenia

   Thrombocytopenia

   Platelet Transfusionse

   Lymphopenia

89

39

79

85

21

75

22

 

22

25

 

25

3

 

35

25

 

18

67

13

20

13

<1

51

6

 

3

3

 

12

1

 

1

1

 

5

Hepatic

   Increased

   Transaminases

   Increased Alkaline    Phosphatase

22

 

19

2

 

1

1

 

0

10

 

13

1

 

0

0

 

0

Renal

   Proteinuria

   Hematuria

   Elevated creatinine

23

15

38

0

0

4

0

0

<1

18

13

31

0

0

2

0

0

<1

Other Laboratory

   Hyperglycemia

   Hypomagnesemia

   Hypocalcemia

30

30

18

4

4

2

0

3

0

23

17

7

3

2

0

0

0

<1

Non-laboratoryf

   Nausea

   Vomiting

   Alopecia

   Neuro Motor

   Diarrhea

   Neuro Sensory

   Infection

   Fever

   Neuro Cortical

   Neuro Mood

   Local

   Neuro Headache

   Stomatitis

   Hemorrhage

   Hypotension

   Rash


93

78

53

35

24

23

18

16

16

16

15

14

14

14

12

11


25

11

1

12

2

1

3

0

3

1

0

0

1

1

1

0


2

12

0

0

2

0

2

0

1

0

0

0

0

0

0

0


87

71

33

15

13

18

12

5

9

10

6

7

5

4

7

3


20

10

0

3

0

1

1

0

1

1

0

0

0

0

1

0


<1

9

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Table 7 presents the incidence of selected adverse reactions, occurring in ≥10% of gemcitabine-treated patients and at a higher incidence in the gemcitabine plus cisplatin arm, reported in a randomized trial of gemcitabine plus cisplatin (n=69) administered in 21-day cycles as compared to etoposide plus cisplatin alone (n=66) in patients receiving first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) [see Clinical Studies (14.3)]. A listing of clinically significant adverse reactions is provided following the table.

Patients in the gemcitabine cisplatin (GC) arm received a median of 5 cycles and those in the etoposide/cisplatin (EC) arm received a median of 4 cycles. The majority of patients receiving more than one cycle of treatment required dose adjustments; 81% in the (GC) arm and 68% in the (EC) arm. The incidence of hospitalizations for treatment-related adverse events was 22% (GC) and 27% in the (EC) arm. The proportion of discontinuation of treatment for treatment-related adverse reactions was higher for patients in the (GC) arm (14% versus 8%). The proportion of patients hospitalized for febrile neutropenia was lower in the (GC) arm (7% versus 12%). There was one death attributed to treatment, a patient with febrile neutropenia and renal failure, which occurred in the gemcitabine/cisplatin arm.

Table 7: Per-Patient Incidence of Selected Adverse Reactions in Randomized Trial of Gemcitabine Plus Cisplatin versus Etoposide Plus Cisplatin in patients with NSCLCa
a      Grade based on criteria from the World Health Organization (WHO).
b      N=67-69; all gemcitabine plus cisplatin patients with laboratory or non-laboratory data. Gemcitabine at 1,250 mg/m2 on Days 1 and 8 and cisplatin at 100 mg/m2 on Day 1 every 21 days.
c      N=57-63; all cisplatin plus etoposide patients with laboratory or non-laboratory data. Cisplatin at 100 mg/m2 on Day 1 and intravenous etoposide at 100 mg/m2 on Days 1, 2, and 3 every 21 days.
d      Regardless of causality.
e      WHO grading scale not applicable to proportion of patients with transfusions.
f      Non-laboratory events were graded only if assessed to be possibly drug-related. Pain data were not collected.
g      Flu-like syndrome and edema were not graded.

Gemcitabine plus Cisplatinb

Etoposide plus Cisplatinc

All Grades

Grade 3

Grade 4

All Grades

Grade 3

Grade 4

Laboratoryd

Hematologic

   Anemia

   RBC Transfusionse

   Neutropenia

   Thrombocytopenia

   Platelet Transfusionse

88

29

88

81

3

22

-

36

39

-

0

-

28

16

-

77

21

87

45

8

13

-

20

8

-

2

-

56

5

-

Hepatic

   Increased ALT

   Increased AST

   Increased Alkaline

   Phosphatase

   Bilirubin

6

3

16

 

0

0

0

0

 

0

0

0

0

 

0

12

11

11

 

0

0

0

0

 

0

0

0

0

 

0

Renal

   Proteinuria

   Hematuria

   BUN

   Creatinine

12

22

6

2

0

0

0

0

0

0

0

0

5

10

4

2

0

0

0

0

0

0

0

0

Non-laboratoryf

   Nausea and Vomiting

   Fever

   Rash

   Dyspnea

   Diarrhea

   Hemorrhage

   Infection

   Alopecia

   Stomatitis

   Somnolence

   Paresthesias

   Flu-like syndromeg

   Edemag

96

6

10

1

14

9

28

77

20

3

38

3

12

35

0

0

0

1

0

3

13

4

0

0

-

-

4

0

0

1

1

3

1

0

0

0

0

-

-

86

3

3

3

13

3

21

92

18

3

16

0

2

19

0

0

0

0

0

8

51

2

2

2

-

-

7

0

0

0

2

3

0

0

0

0

0

-

-

Breast Cancer:

Table 8 presents the incidence of selected adverse reactions, occurring in ≥10% of gemcitabine-treated patients and at a higher incidence in the gemcitabine plus paclitaxel arm, reported in a randomized trial of gemcitabine plus paclitaxel (n=262) compared to paclitaxel alone (n=259) for the first-line treatment of metastatic breast cancer (MBC) in women who received anthracycline-containing chemotherapy in the adjuvant/neo-adjuvant setting or for whom anthracyclines were contraindicated [see Clinical Studies (14.2)].

The requirement for dose reduction of paclitaxel were higher for patients in the gemcitabine/paclitaxel arm (5% versus 2%). The number of paclitaxel doses omitted (<1%), the proportion of patients discontinuing treatment for treatment-related adverse reactions (7% versus 5%), and the number of treatment-related deaths (1 patient in each arm) were similar between the two arms.

Table 8: Per-Patient Incidence of Selected Adverse Reactions from Comparative Trial of Gemcitabine Plus Paclitaxel Versus Single-Agent Paclitaxel in Breast Cancera Occurring at Higher Incidence in Gemcitabine-Treated Patients [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)]
a      Severity grade based on National Cancer Institute Common Toxicity Criteria (CTC) Version 2.0.
b      Regardless of causality.
c      Non-laboratory events were graded only if assessed to be possibly drug-related.

Gemcitabine plus Paclitaxel

(N=262)

Paclitaxel

(N=259)

All Grades

Grade 3

Grade 4

All Grades

Grade 3

Grade 4

Laboratoryb

Hematologic

   Anemia

   Neutropenia

   Thrombocytopenia

69

69

26

6

31

5

1

17

<1

51

31

7

3

4

<1

<1

7

<1

Hepatobiliary

   Increased ALT

   Increased AST

18

16

5

2

<1

0

6

5

<1

<1

0

0

Non-laboratoryc

   Alopecia

   Neuropathy-sensory

   Nausea

   Fatigue

   Vomiting

   Diarrhea

   Anorexia

   Neuropathy-motor

   Stomatitis/pharyngitis

   Fever

   Rash/desquamation

   Febrile neutropenia

90

64

50

40

29

20

17

15

13

13

11

6

14

5

1

6

2

3

0

2

1

<1

<1

5

4

<1

0

<1

0

0

0

<1

<1

0

<1

<1

92

58

31

28

15

13

12

10

8

3

5

2

19

3

2

1

2

2

<1

<1

<1

0

0

1

3

0

0

<1

0

0

0

0

0

0

0

0

Clinically relevant Grade 3 or 4 dyspnea occurred with a higher incidence in the gemcitabine plus paclitaxel arm compared with the paclitaxel arm (1.9% versus 0).

Ovarian Cancer:

Table 9 presents the incidence of selected adverse reactions, occurring in ≥10% of gemcitabine-treated patients and at a higher incidence in the gemcitabine plus carboplatin arm, reported in a randomized trial of gemcitabine plus carboplatin (n=175) compared to carboplatin alone (n=174) for the second-line treatment of ovarian cancer in women with disease that had relapsed more than 6 months following first-line platinum-based chemotherapy [see Clinical Studies (14.1)]. Additional clinically significant adverse reactions, occurring in less than 10% of patients, are provided following Table 9.

The proportion of patients with dose adjustments for carboplatin (1.8% versus 3.8%), doses of carboplatin omitted (0.2% versus 0), and discontinuing treatment for treatment-related adverse reactions (10.9% versus 9.8%), were similar between arms. Dose adjustment for gemcitabine occurred in 10.4% of patients and gemcitabine dose was omitted in 13.7% of patients in the gemcitabine/carboplatin arm.

Table 9: Per-Patient Incidence of Adverse Reactions in Randomized Trial of Gemcitabine Plus Carboplatin Versus Carboplatin in Ovarian Cancera Occurring at Higher Incidence in Gemcitabine-Treated Patients [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)]
a      Grade based on Common Toxicity Criteria (CTC) Version 2.0.
b      Regardless of causality.
c      Percent of patients receiving transfusions. Transfusions are not CTC-graded events. Blood transfusions included both packed red blood cells and whole blood.

Gemcitabine plus Carboplatin

(N=175)

Carboplatin

(N=174)

All Grades

Grade 3

Grade 4

All Grades

Grade 3

Grade 4

Laboratoryb

Hematologic

   Neutropenia

   Anemia

   Thrombocytopenia

   RBC Transfusionsc

   Platelet Transfusionsc

90

86

78

38

9

42

22

30

-

-

29

6

5

-

-

58

75

57

15

3

11

9

10

-

-

1

2

1

-

-

Non-laboratoryb

   Nausea

   Alopecia

   Vomiting

   Constipation

   Fatigue

   Diarrhea

   Stomatitis/pharyngitis

69

49

46

42

40

25

22

6

0

6

6

3

3

<1

0

0

0

1

<1

0

0

61

17

36

37

32

14

13

3

0

2

3

5

<1

0

0

0

<1

0

0

0

0

Hematopoietic growth factors were administered more frequently in the gemcitabine-containing arm: granulocyte growth factors (23.6% and 10.1%) and erythropoietic agents (7.3% and 3.9%).

The following clinically relevant, Grade 3 and 4 adverse reactions occurred more frequently in the gemcitabine plus carboplatin arm: dyspnea (3.4% versus 2.9%), febrile neutropenia (1.1% versus 0), hemorrhagic event (2.3% versus 1.1%), motor neuropathy (1.1% versus 0.6%), and rash/desquamation (0.6% versus 0).

6.2 Post-Marketing Experience

The following adverse reactions have been identified during post-approval use of gemcitabine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Cardiovascular - Congestive heart failure, myocardial infarction, arrhythmias, supraventricular arrhythmias

Vascular Disorders - Peripheral vasculitis, gangrene, and capillary leak syndrome [see Warnings and Precautions (5.8)]

Skin - Cellulitis, severe skin reactions, including desquamation and bullous skin eruptions

Hepatic - Hepatic failure, hepatic veno-occlusive disease

Pulmonary - Interstitial pneumonitis, pulmonary fibrosis, pulmonary edema, and adult respiratory distress syndrome (ARDS)

Nervous System – Posterior reversible encephalopathy syndrome (PRES) [see Warnings and Precautions (5.9)]

7 DRUG INTERACTIONS

No drug interaction studies have been conducted.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category D [see Warnings and Precautions (5.6)].

Risk Summary

Gemcitabine can cause fetal harm when administered to a pregnant woman. Based on its mechanism of action, gemcitabine is expected to result in adverse reproductive effects. Gemcitabine was teratogenic, embryotoxic, and fetotoxic in mice and rabbits. If gemcitabine is used during pregnancy, or if the patient becomes pregnant while taking gemcitabine, the patient should be apprised of the potential hazard to a fetus.

Animal Data

Gemcitabine is embryotoxic causing fetal malformations (cleft palate, incomplete ossification) at doses of 1.5 mg/kg/day in mice (approximately 0.005 times the recommended human dose on a mg/m2 basis). Gemcitabine is fetotoxic causing fetal malformations (fused pulmonary artery, absence of gall bladder) at doses of 0.1 mg/kg/day in rabbits (about 0.002 times the recommended human dose on a mg/m2 basis). Embryotoxicity was characterized by decreased fetal viability, reduced live litter sizes, and developmental delays [see Warnings and Precautions (5.6)].

8.3 Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from gemcitabine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

8.4 Pediatric Use

The safety and effectiveness of gemcitabine have not been established in pediatric patients. The safety and pharmacokinetics of gemcitabine were evaluated in a trial in pediatric patients with refractory leukemia. The maximum tolerated dose was 10 mg/m2/min for 360 minutes three times weekly followed by a one-week rest period. The safety and activity of gemcitabine were evaluated in a trial of pediatric patients with relapsed acute lymphoblastic leukemia (22 patients) and acute myelogenous leukemia (10 patients) at a dose of 10 mg/m2/min administered over 360 minutes three times weekly followed by a one-week rest period. Toxicities observed included bone marrow suppression, febrile neutropenia, elevation of serum transaminases, nausea, and rash/desquamation. No meaningful clinical activity was observed in this trial.

8.5 Geriatric Use

In clinical studies of gemcitabine, enrolling 979 patients with various cancers who received gemcitabine as a single agent, no overall differences in safety were observed between patients aged 65 and older and younger patients, with the exception of a higher rate of Grade 3 - 4 thrombocytopenia in older patients as compared to younger patients. In a randomized trial in women with ovarian cancer, 175 women received gemcitabine plus carboplatin, of which 29% were age 65 years or older. Similar effectiveness was observed between older and younger women. There was significantly higher Grade 3/4 neutropenia in women 65 years of age or older.

Gemcitabine clearance is affected by age, however there are no recommended dose adjustments based on patients' age [see Clinical Pharmacology (12.3)].

8.6 Renal Impairment

No clinical studies have been conducted with gemcitabine in patients with decreased renal function.

8.7 Hepatic Impairment

No clinical studies have been conducted with gemcitabine in patients with decreased hepatic function.

8.8 Gender

Gemcitabine clearance is affected by gender [see Clinical Pharmacology (12.3)]. In single-agent studies of gemcitabine, women, especially older women, were more likely not to proceed to a subsequent cycle and to experience Grade 3-4 neutropenia and thrombocytopenia.

10 OVERDOSAGE

Myelosuppression, paresthesias, and severe rash were the principal toxicities seen when a single dose as high as 5,700 mg/m2 was administered by intravenous infusion over 30 minutes every 2 weeks to several patients in a dose-escalation study.

11 DESCRIPTION

Gemcitabine is a nucleoside metabolic inhibitor that exhibits antitumor activity. Gemcitabine HCl is 2´-deoxy-2´,2´-difluorocytidine monohydrochloride (β-isomer).

The structural formula is as follows:

structural formula gemcitabine

The empirical formula for gemcitabine HCl is C9H11F2N3O4 • HCl. It has a molecular weight of 299.66.

Gemcitabine HCl is a white to off-white solid. It is soluble in water, slightly soluble in methanol, and practically insoluble in ethanol and polar organic solvents.

The clinical formulation is supplied in a sterile form for intravenous use only. Vials of gemcitabine for injection, USP contain 2 g of gemcitabine HCl (expressed as free base) formulated with mannitol (2 g) and sodium acetate (125 mg) as a sterile lyophilized powder. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Gemcitabine kills cells undergoing DNA synthesis and blocks the progression of cells through the G1/S-phase boundary. Gemcitabine is metabolized by nucleoside kinases to diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. Gemcitabine diphosphate inhibits ribonucleotide reductase, an enzyme responsible for catalyzing the reactions that generate deoxynucleoside triphosphates for DNA synthesis, resulting in reductions in deoxynucleotide concentrations, including dCTP. Gemcitabine triphosphate competes with dCTP for incorporation into DNA. The reduction in the intracellular concentration of dCTP by the action of the diphosphate enhances the incorporation of gemcitabine triphosphate into DNA (self-potentiation). After the gemcitabine nucleotide is incorporated into DNA, only one additional nucleotide is added to the growing DNA strands, which eventually results in the initiation of apoptotic cell death.

12.3 Pharmacokinetics

Absorption and Distribution

The pharmacokinetics of gemcitabine were examined in 353 patients, with various solid tumors. Pharmacokinetic parameters were derived using data from patients treated for varying durations of therapy given weekly with periodic rest weeks and using both short infusions (<70 minutes) and long infusions (70 to 285 minutes). The total gemcitabine dose varied from 500 to 3,600 mg/m2.

The volume of distribution was increased with infusion length. Volume of distribution of gemcitabine was 50 L/m2 following infusions lasting <70 minutes. For long infusions, the volume of distribution rose to 370 L/m2.

Gemcitabine pharmacokinetics are linear and are described by a 2-compartment model. Population pharmacokinetic analyses of combined single and multiple dose studies showed that the volume of distribution of gemcitabine was significantly influenced by duration of infusion and gender. Gemcitabine plasma protein binding is negligible.

Metabolism

Gemcitabine disposition was studied in 5 patients who received a single 1,000 mg/m2/30 minute infusion of radiolabeled drug. Within one (1) week, 92% to 98% of the dose was recovered, almost entirely in the urine. Gemcitabine (<10%) and the inactive uracil metabolite, 2´-deoxy-2´,2´-difluorouridine (dFdU), accounted for 99% of the excreted dose. The metabolite dFdU is also found in plasma.

The active metabolite, gemcitabine triphosphate, can be extracted from peripheral blood mononuclear cells. The half-life of the terminal phase for gemcitabine triphosphate from mononuclear cells ranges from 1.7 to 19.4 hours.

Elimination

Clearance of gemcitabine was affected by age and gender. The lower clearance in women and the elderly results in higher concentrations of gemcitabine for any given dose. Differences in either clearance or volume of distribution based on patient characteristics or the duration of infusion result in changes in half-life and plasma concentrations. Table 10 shows plasma clearance and half-life of gemcitabine following short infusions for typical patients by age and gender.

Table 10: Gemcitabine Clearance and Half-Life for the "Typical" Patient
a       Half-life for patients receiving <70 minute infusion.

Age

Clearance

Men

(L/hr/m2)

Clearance

Women

(L/hr/m2)

Half-Lifea

Men

(min)

Half-Lifea

Women

(min)

29

92.2

69.4

42

49

45

75.7

57.0

48

57

65

55.1

41.5

61

73

79

40.7

30.7

79

94

Gemcitabine half-life for short infusions ranged from 42 to 94 minutes, and the value for long infusions varied from 245 to 638 minutes, depending on age and gender, reflecting a greatly increased volume of distribution with longer infusions.

Drug Interactions

When gemcitabine (1,250 mg/m2 on Days 1 and 8) and cisplatin (75 mg/m2 on Day 1) were administered in NSCLC patients, the clearance of gemcitabine on Day 1 was 128 L/hr/m2 and on Day 8 was 107 L/hr/m2. Analysis of data from metastatic breast cancer patients shows that, on average, gemcitabine has little or no effect on the pharmacokinetics (clearance and half-life) of paclitaxel and paclitaxel has little or no effect on the pharmacokinetics of gemcitabine. Data from NSCLC patients demonstrate that gemcitabine and carboplatin given in combination does not alter the pharmacokinetics of gemcitabine or carboplatin compared to administration of either single-agent. However, due to wide confidence intervals and small sample size, interpatient variability may be observed.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term animal studies to evaluate the carcinogenic potential of gemcitabine have not been conducted. Gemcitabine was mutagenic in an in vitro mouse lymphoma (L5178Y) assay and was clastogenic in an in vivo mouse micronucleus assay. Gemcitabine IP doses of 0.5 mg/kg/day (about 1/700 the human dose on a mg/m2 basis) in male mice had an effect on fertility with moderate to severe hypospermatogenesis, decreased fertility, and decreased implantations. In female mice, fertility was not affected but maternal toxicities were observed at 1.5 mg/kg/day administered intravenously (about 1/200 the human dose on a mg/m2 basis) and fetotoxicity or embryolethality was observed at 0.25 mg/kg/day administered intravenously (about 1/1,300 the human dose on a mg/m2 basis).

14 CLINICAL STUDIES

14.1 Ovarian Cancer

The safety and efficacy of gemcitabine was studied in a randomized trial of 356 women with advanced ovarian cancer that had relapsed at least 6 months after first-line platinum-based therapy. Patients were randomized to receive either gemcitabine 1,000 mg/m2 on Days 1 and 8 of a 21-day cycle and carboplatin AUC 4 administered after gemcitabine infusion on Day 1 of each cycle (n=178) or to carboplatin AUC 5 administered on Day 1 of each 21-day cycle (n=178). The primary efficacy outcome measure was progression free survival (PFS).

Patient characteristics are shown in Table 11. The addition of gemcitabine to carboplatin resulted in statistically significant improvements in PFS and overall response rate as shown in Table 12 and Figure 1. Approximately 75% of patients in each arm received additional chemotherapy for disease progression; 13 of 120 patients in the carboplatin alone arm received gemcitabine for treatment of disease progression. There was no significant difference in overall survival between the treatment arms.

Table 11: Randomized Trial of Gemcitabine Plus Carboplatin Versus Carboplatin in Ovarian Cancer - Baseline Demographics and Clinical Characteristics
a      5 patients on gemcitabine plus carboplatin arm and 4 patients on the carboplatin arm with no baseline Eastern Cooperative Oncology Group (ECOG) performance status.
b      2 on gemcitabine plus carboplatin arm and 1 on carboplatin arm had a platinum-free interval <6 months.

Gemcitabine/Carboplatin

Carboplatin

Number of randomized patients

178

178

Median age, years

   Range

59

36 to 78

58

21 to 81

Baseline ECOG performance status 0-1a

94%

95%

Disease Status

   Evaluable

   Bidimensionally measurable

8%

92%

3%

96%

Platinum-free intervalb

   6-12 months

   >12 months

40%

59%

40%

60%

First-line therapy

   Platinum-taxane combination

   Platinum-non-taxane combination

   Platinum monotherapy

70%

29%

1%

71%

28%

1%

Table 12: Randomized Trial of Gemcitabine Plus Carboplatin Versus Carboplatin in Ovarian Cancer - Efficacy Outcomes
a      CI=confidence interval.
b      Log Rank, unadjusted.
c      Chi Square.
d      CR=Complete response.
e      PR plus PRNM=Partial response plus partial response, non-measurable disease.
f       Independently reviewed cohort - gemcitabine/carboplatin (n=121), carboplatin (n=101); independent reviewers unable to measure disease detected by sonography or physical exam.

Gemcitabine/Carboplatin

(N=178)

Carboplatin

(N=178)

Progression-free Survival

   Median (95% CIa) months

8.6 (8.0, 9.7)

5.8 (5.2, 7.1)

   Hazard Ratio (95% CI)

0.72 (0.57, 0.90)

   p-valueb

p=0.0038

Overall Survival

   Median (95% CI) months

18.0 (16.2, 20.3)

17.3 (15.2, 19.3)

   Hazard Ratio (95% CI)

0.98 (0.78, 1.24)

   p-valueb

p=0.8977

Investigator Reviewed

   Overall Response Rate

47.2%

30.9%

   p-valuec

p=0.0016

   CRd

   PR plus PRNMe

14.6%

32.6%

6.2%

24.7%

Independently Reviewed

   Overall Response Ratef

46.3%

35.6%

   p-valuec

p=0.11

   CRd

   PR plus PRNMe

9.1%

37.2%

4.0%

31.7%

Figure 1: Kaplan-Meier Curve of Progression Free Survival in Gemcitabine Plus Carboplatin Versus Carboplatin in Ovarian Cancer (N=356)

Figure 1: Kaplan-Meier Curve of Progression Free Survival in Gemcitabine Plus Carboplatin Versus Carboplatin in Ovarian Cancer

14.2 Breast Cancer

The safety and efficacy of gemcitabine were evaluated in a multi-national, randomized, open-label trial conducted in women receiving initial treatment for metastatic breast cancer in women who have received prior adjuvant/neoadjuvant anthracycline chemotherapy unless clinically contraindicated. Patients were randomized to receive gemcitabine 1,250 mg/m2 was administered on Days 1 and 8 of a 21-day cycle and paclitaxel 175 mg/m2 administered prior to gemcitabine on Day 1 of each cycle (n=267) or to receive paclitaxel 175 mg/m2 was administered on Day 1 of each 21-day cycle (n=262). The primary efficacy outcome measure was time to documented disease progression.

A total of 529 patients were enrolled; 267 were randomized to gemcitabine and paclitaxel and 262 to paclitaxel alone. Demographic and baseline characteristics were similar between treatment arms (see Table 13). Efficacy results are presented in Table 13 and Figure 2. The addition of gemcitabine to paclitaxel resulted in statistically significant improvement in time to documented disease progression and overall response rate compared to paclitaxel alone. There was no significant difference in overall survival.

Table 13: Randomized Trial of Gemcitabine Plus Paclitaxel Versus Paclitaxel in Breast Cancer
a      Karnofsky Performance Status.
b      These represent reconciliation of investigator and Independent Review Committee assessments according to a predefined algorithm.
c      Based on the ITT population.

Gemcitabine/Paclitaxel

Paclitaxel

Number of patients

267

262

Demographic/Entry Characteristics

Median age (years)

   Range

53

26 to 83

52

26 to 75

Metastatic disease

97%

97%

Baseline KPSa ≥90

70%

74%

Number of tumor sites

   1-2

   ≥3

57%

43%

59%

41%

Visceral disease

73%

73%

Prior anthracycline

97%

96%

Efficacy Outcomes

Time to Documented Disease Progressionb

   Median in months

(95% CI)

5.2

(4.2, 5.6)

2.9

(2.6, 3.7)

   Hazard Ratio (95% CI)

0.650 (0.524, 0.805)

   p-value

p<0.0001

   Overall Survivalc

   Median Survival in months

(95% CI)

18.6

(16.5, 20.7)

15.8

(14.1, 17.3)

   Hazard Ratio (95% CI)

0.86 (0.71, 1.04)

   p-value

Not Significant

   Overall Response Rate

(95% CI)

40.8%

(34.9, 46.7)

22.1%

(17.1, 27.2)

   p-value

p<0.0001

Figure 2: Kaplan-Meier Curve of Time to Documented Disease Progression in Gemcitabine Plus Paclitaxel Versus Paclitaxel Breast Cancer Study (N=529)

Figure 2: Kaplan-Meier Curve of Time to Documented Disease Progression in Gemcitabine Plus Paclitaxel Versus Paclitaxel Breast Cancer Study

14.3 Non-Small Cell Lung Cancer (NSCLC)

The safety and efficacy of gemcitabine was evaluated in two randomized, multicenter trials.

28-Day Schedule

A multinational, randomized trial compared gemcitabine plus cisplatin to cisplatin alone in the treatment of patients with inoperable Stage IIIA, IIIB, or IV NSCLC who had not received prior chemotherapy. Patients were randomized to receive gemcitabine 1,000 mg/m2 on Days 1, 8, and 15 of a 28-day cycle with cisplatin 100 mg/m2 administered on Day 1 of each cycle or to receive cisplatin 100 mg/m2 on Day 1 of each 28-day cycle. The primary efficacy outcome measure was overall survival. A total of 522 patients were enrolled at clinical centers in Europe, the US, and Canada. Patient demographics and baseline characteristics (shown in Table 14) were similar between arms with the exception of histologic subtype of NSCLC, with 48% of patients on the cisplatin arm and 37% of patients on the gemcitabine plus cisplatin arm having adenocarcinoma. Efficacy results are presented in Table 14 and Figure 3 for overall survival.

21-Day Schedule

A randomized (1:1), multicenter trial was conducted in 135 patients with Stage IIIB or IV NSCLC. Patients were randomized to receive gemcitabine 1,250 mg/m2 on Days 1 and 8, and cisplatin 100 mg/m2 on Day 1 of a 21-day cycle or to receive etoposide 100 mg/m2 intravenously on Days 1, 2, and 3 and cisplatin 100 mg/m2 on Day 1 of a 21-day cycle.

There was no significant difference in survival between the two treatment arms (Log rank p=0.18, two-sided, see Table 14). The median survival was 8.7 months for the gemcitabine plus cisplatin arm versus 7.0 months for the etoposide plus cisplatin arm. Median time to disease progression for the gemcitabine plus cisplatin arm was 5.0 months compared to 4.1 months on the etoposide plus cisplatin arm (Log rank p=0.015, two-sided). The objective response rate for the gemcitabine plus cisplatin arm was 33% compared to 14% on the etoposide plus cisplatin arm (Fisher's Exact p=0.01, two-sided).

Figure 3: Kaplan-Meier Survival Curve in Gemcitabine Plus Cisplatin Versus Cisplatin NSCLC Study (N=522).

xen-1822-4Figure 3: Kaplan-Meier Survival Curve in Gemcitabine Plus Cisplatin Versus Cisplatin NSCLC Study
Table 14: Randomized Trials of Gemcitabine Plus Cisplatin in Patients with NSCLC
a     28-day schedule — Gemcitabine plus cisplatin: gemcitabine 1,000 mg/m2 on Days 1, 8, and 15 and cisplatin 100 mg/m2 on Day 1 every 28 days; Single-agent cisplatin: cisplatin 100 mg/m2 on Day 1 every 28 days.
b     21-day schedule — Gemcitabine plus cisplatin: gemcitabine 1,250 mg/m2 on Days 1 and 8 and cisplatin 100 mg/m2 on Day 1 every 21 days; Etoposide plus cisplatin: cisplatin 100 mg/m2 on Day 1 and intravenous etoposide 100 mg/m2 on Days 1, 2, and 3 every 21 days.
c     N/A - Not applicable.
d     Karnofsky Performance Status.
e     CI=confidence intervals.
f     p-value two-sided Fisher's Exact test for difference in binomial proportions; log rank test for time-to-event analyses.

Trial

28-day Schedulea

21-day Scheduleb

Treatment Arm

Gemcitabine plus Cisplatin

Cisplatin

Gemcitabine plus Cisplatin

Etoposide plus Cisplatin

Number of patients

260

262

69

66

Demographic/Entry Characteristics

   Male

Median age, years

   Range

70%

62

36 to 88

71%

63

35 to 79

93%

58

33 to 76

92%

60

35 to 75

Stage IIIA

7%

7%

N/Ac

N/Ac

Stage IIIB

26%

23%

48%

52%

Stage IV

67%

70%

52%

49%

Baseline KPSd 70 to 80

41%

44%

45%

52%

Baseline KPSd 90 to 100

57%

55%

55%

49%

Efficacy Outcomes

Survival

   Median in months

   (95% CIe) months

9.0

8.2, 11.0

7.6

6.6, 8.8

8.7

7.8, 10.1

7.0

6.0, 9.7

p-valuef

p=0.008

p=0.18

Time to Disease Progression

   Median in months

   (95% CIe) months

5.2

4.2, 5.7

3.7

3.0, 4.3

5.0

4.2, 6.4

4.1

2.4, 4.5

   p-valuef

p=0.009

p=0.015

Tumor Response

26%

10%

33%

14%

   p-valuef

p<0.0001

p=0.01

14.4 Pancreatic Cancer

The safety and efficacy of gemcitabine was evaluated in two trials, a randomized, single-blind, two-arm, active-controlled trial conducted in patients with locally advanced or metastatic pancreatic cancer who had received no prior chemotherapy and in a single-arm, open-label, multicenter trial conducted in patients with locally advanced or metastatic pancreatic cancer previously treated with 5-FU or a 5-FU-containing regimen. The first trial randomized patients to receive gemcitabine 1,000 mg/m2 intravenously over 30 minutes once weekly for 7 weeks followed by a one-week rest, then once weekly dosing for 3 consecutive weeks every 28-days in subsequent cycles (n=63) or to 5-fluorouracil (5-FU) 600 mg/m2 intravenously over 30 minutes once weekly (n=63). In the second trial, all patients received gemcitabine 1,000 mg/m2 intravenously over 30 minutes once weekly for 7 weeks followed by a one-week rest, then once weekly dosing for 3 consecutive weeks every 28-days in subsequent cycles. The primary efficacy outcome measure in both trials was "clinical benefit response". A patient was considered to have had a clinical benefit response if either of the following occurred:

i)
The patient achieved a ≥50% reduction in pain intensity (Memorial Pain Assessment Card) or analgesic consumption, or a 20-point or greater improvement in performance status (Karnofsky Performance Status) for a period of at least 4 consecutive weeks, without showing any sustained worsening in any of the other parameters. Sustained worsening was defined as 4 consecutive weeks with either any increase in pain intensity or analgesic consumption or a 20-point decrease in performance status occurring during the first 12 weeks of therapy.

OR:

ii)
The patient was stable on all of the aforementioned parameters, and showed a marked, sustained weight gain (≥7% increase maintained for ≥4 weeks) not due to fluid accumulation.

The randomized trial enrolled 126 patients across 17 sites in the US and Canada. The demographic and entry characteristics were similar between the arms (Table 15). The efficacy outcome results are shown in Table 15 and for overall survival in Figure 4. Patients treated with gemcitabine had statistically significant increases in clinical benefit response, survival, and time to disease progression compared to those randomized to receive 5-FU. No confirmed objective tumor responses were observed in either treatment arm.

Table 15: Randomized Trial of Gemcitabine Versus 5-Fluorouracil in Pancreatic Cancer
a      Karnofsky Performance Status.
b      p-value for clinical benefit response was calculated using the two-sided test for difference in binomial proportions. All other p-values are calculated using the log rank test.

Gemcitabine

5-FU

Number of patients

63

63

Demographic/Entry Characteristics

   Male

Median age

   Range

Stage IV disease

Baseline KPSa ≤70

54%

62 years

37 to 79

71%

70%

54%

61 years

36 to 77

76%

68%

Efficacy Outcomes

Clinical benefit response

22.2%

4.8%

   p-valueb

p=0.004

Survival

   Median

   (95% CI)

5.7 months

(4.7, 6.9)

4.2 months

(3.1, 5.1)

   p-valueb

p=0.0009

Time to Disease Progression

   Median

   (95% CI)

2.1 months

(1.9, 3.4)

0.9 months

(0.9, 1.1)

   p-valueb

p=0.0013

Figure 4: Kaplan-Meier Survival Curve

Figure 4: Kaplan-Meier Survival Curve

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

Gemcitabine for injection, USP is available in sterile single-dose vials individually packaged in a carton containing:

2 g white to off-white, lyophilized powder in a 100-mL size sterile single-dose vial - NDC 0409-0187-01

16.2 Storage and Handling

Unopened vials of gemcitabine for injection, USP are stable until the expiration date indicated on the package when stored at controlled room temperature 20° to 25°C (68° to 77°F) and that allows for excursions between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature] [see Dosage and Administration (2.6 and 2.7)].

17 PATIENT COUNSELING INFORMATION

Advise patients of the risks of low blood cell counts and the potential need for blood transfusions and increased susceptibility to infections. Instruct patients to immediately contact their healthcare provider for development of signs or symptoms of infection, fever, prolonged or unexpected bleeding, bruising, or shortness of breath [see Warnings and Precautions (5.2)].
Advise patients of the risks of pulmonary toxicity including respiratory failure and death. Instruct patients to immediately contact their healthcare provider for development of shortness of breath, wheezing, or cough [see Warnings and Precautions (5.3)].
Advise patients of the risks of hemolytic-uremic syndrome and associated renal failure. Instruct patients to immediately contact their healthcare provider for changes in the color or volume of urine output or for increased bruising or bleeding [see Warnings and Precautions (5.4)].
Advise patients of the risks of hepatic toxicity including liver failure and death. Instruct patients to immediately contact their healthcare provider for signs of jaundice or for pain/tenderness in the right upper abdominal quadrant [see Warnings and Precautions (5.5)].

Manufactured by:
Hospira Australia Pty Ltd
Mulgrave VIC 3170
Australia

Manufactured for:

Hospira logo

Hospira, Inc., Lake Forest, IL 60045 USA  

Product of Australia

LAB-0919-1.0

Revised: 5/2017
Document Id: c7827741-4e9e-4065-a0e3-3e9e033e9f95
Set id: a625c92b-c569-4b98-8d2e-2b3f5e12b34f
Version: 19
Effective Time: 20170501
 
Hospira, Inc.